These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 18057913)

  • 21. Biosimilars--science, status, and strategic perspective.
    Kresse GB
    Eur J Pharm Biopharm; 2009 Aug; 72(3):479-86. PubMed ID: 19286455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biosimilars: current status and future directions.
    Roger SD
    Expert Opin Biol Ther; 2010 Jul; 10(7):1011-8. PubMed ID: 20384525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biosimilars: policy, clinical, and regulatory considerations.
    Gottlieb S
    Am J Health Syst Pharm; 2008 Jul; 65(14 Suppl 6):S2-8. PubMed ID: 18591712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-clinical safety studies on biosimilar recombinant human erythropoietin.
    Parnham MJ; Schindler-Horvat J; Kozlović M
    Basic Clin Pharmacol Toxicol; 2007 Feb; 100(2):73-83. PubMed ID: 17244255
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biosimilars: it's not as simple as cost alone.
    Roger SD; Goldsmith D
    J Clin Pharm Ther; 2008 Oct; 33(5):459-64. PubMed ID: 18834359
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The story of biosimilars--chance or threat?].
    Woroń J; Kocić I
    Pol Merkur Lekarski; 2014 Nov; 37(221):311-5. PubMed ID: 25546996
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Biosimilars versus original biologics. Similarities and differences from development to approval].
    Windisch J
    Z Rheumatol; 2015 Oct; 74(8):672-81. PubMed ID: 26323591
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ten years' clinical experience with biosimilar human growth hormone: a review of efficacy data.
    López-Siguero JP; Pfäffle R; Chanson P; Szalecki M; Höbel N; Zabransky M
    Drug Des Devel Ther; 2017; 11():1489-1495. PubMed ID: 28553079
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative testing and pharmacovigilance of biosimilars.
    Locatelli F; Roger S
    Nephrol Dial Transplant; 2006 Oct; 21 Suppl 5():v13-6. PubMed ID: 16959789
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Legal regulations to produce serum eye drops : when is it necessary, and how can it be obtained?].
    Geerling G; Grus F; Seitz B; Hartwig D; Schirra F
    Ophthalmologe; 2008 Jul; 105(7):632-8. PubMed ID: 18587585
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulatory guidelines for biosimilars in Malaysia.
    Abas A
    Biologicals; 2011 Sep; 39(5):339-42. PubMed ID: 21784655
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Regulatory aspects of biosimilars. Myths and facts].
    Schneider CK; Weise M
    Z Rheumatol; 2015 Oct; 74(8):695-700. PubMed ID: 26385104
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How similar do 'biosimilars' need to be?
    Schellekens H
    Nat Biotechnol; 2004 Nov; 22(11):1357-9. PubMed ID: 15529154
    [No Abstract]   [Full Text] [Related]  

  • 34. Growth hormone treatment for short stature in children born small for gestational age.
    Jung H; Rosilio M; Blum WF; Drop SL
    Adv Ther; 2008 Oct; 25(10):951-78. PubMed ID: 18836868
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ten years of clinical experience with biosimilar human growth hormone: a review of safety data.
    Borrás Pérez MV; Kriström B; Romer T; Walczak M; Höbel N; Zabransky M
    Drug Des Devel Ther; 2017; 11():1497-1503. PubMed ID: 28553080
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Viral safety evaluation of biopharmaceuticals and homoeopathic preparations of human or animal origin.
    Immelmann A
    Pharmeur Sci Notes; 2006 Aug; 2006(1):41-5. PubMed ID: 17694646
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current regulatory and scientific considerations for approving biosimilars in Iran.
    Hadavand N; Valadkhani M; Zarbakhsh A
    Biologicals; 2011 Sep; 39(5):325-7. PubMed ID: 21873077
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Are biosimilars really generics?
    Misra A
    Expert Opin Biol Ther; 2010 Apr; 10(4):489-94. PubMed ID: 20146636
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of biosimilars in the treatment of rheumatic diseases.
    Dörner T; Strand V; Castañeda-Hernández G; Ferraccioli G; Isaacs JD; Kvien TK; Martin-Mola E; Mittendorf T; Smolen JS; Burmester GR
    Ann Rheum Dis; 2013 Mar; 72(3):322-8. PubMed ID: 23253920
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lost in translation: differences in antimicrobial indication approval policies between the United States and Europe.
    Pappas G; Ierodiakonou V; Falagas ME
    Clin Ther; 2009 Jul; 31(7):1595-603. PubMed ID: 19695409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.